B
Bull
Bull · 25%TTNP
$5.14
Szenariopreis
$4.610
-0.173 (-3.76%)Zum Schluss
Loading chart…
- High
- 4.800
- Open
- 4.800
- VWAP
- 4.65
- Vol
- 3.36M
- Mkt Cap
- 5.07M
- Low
- 4.550
- Amount
- 15.63M
- EV/EBITDA, TTM
- 0.00
Titan Pharmaceuticals, Inc. is a pharmaceutical company. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus, and Nalmefene Implant, which is for the prevention of relapse in OUD patients following detoxification from opioids Its product development programs are in non-clinical stages of development.
Analyst Ratings (1)
Hold
0 Buy
1 Hold
0 Sell
Current: 4.61
Tief
—
Durchschnitt
—
Hoch
—
Maxim Group
Hold
—
2022-05-26
Maxim Group
2022-05-26
Kursziel
—
Hold
Maxim Group
Strong Buy
$220
2021-02-18
Maxim Group
2021-02-18
Kursziel
$220
Strong Buy
Maxim Group
Hold
—
2020-08-17
Maxim Group
2020-08-17
Kursziel
—
Hold
Maxim Group
Strong Buy
$600
2019-10-23
Maxim Group
2019-10-23
Kursziel
$600
Strong Buy
Roth Capital
Hold
—
2017-11-10
Roth Capital
2017-11-10
Kursziel
—
Hold
Bewertungskennzahlen
The current forward P/E ratio for Titan Pharmaceuticals Inc (TTNP) is -0.49, compared to its 5-year average forward P/E of -0.75.
Alphio AI Price Scenarios for TTNP
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
8.508-27BenzingaTitan Pharmaceuticals Shares Jump 23% in After-Hours Trading Following Stockholder Endorsement of Three-Way Merger
7.008-06GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SCS, HLVX, BSGM, TTNP on Behalf of Shareholders
7.007-30GlobenewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ITOS, VBTX, TTNP on Behalf of Shareholders July 31, 2025
7.007-29PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BASE, SPTN, TTNP on Behalf of Shareholders
8.507-29GlobenewswireURGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote – Titan Pharmaceuticals, Inc. (Nasdaq: TTNP)
TTNP FAQ — answered by Alphio AI
Titan Pharmaceuticals, Inc. is a pharmaceutical company. Its product pipeline includes Kappa Opioid Receptor Agonist (TP-2021) Implant, which is used for the treatment of moderate-to-severe chronic pruritus, and Nalmefene Implant, which is for the prevention of relapse in OUD patients following detoxification from opioids Its product development programs are in non-clinical stages of development. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
1 analysts cover TTNP: 0 rate it Buy, 1 Hold and 0 Sell.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.